|
Sanofi (SNY) DCF Valuation |
Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
Pré-Construits Pour Une Utilisation Rapide Et Efficace
Compatible MAC/PC, entièrement débloqué
Aucune Expertise N'Est Requise; Facile À Suivre
Sanofi (SNY) Bundle
Streamline your analysis and improve precision with our (SNY) DCF Calculator! Utilizing real data from Sanofi and customizable assumptions, this tool empowers you to forecast, analyze, and evaluate (SNY) as if you were a seasoned investor.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2021 |
AY2 2022 |
AY3 2023 |
AY4 2024 |
AY5 2025 |
FY1 2026 |
FY2 2027 |
FY3 2028 |
FY4 2029 |
FY5 2030 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 45,557.6 | 47,169.4 | 48,398.7 | 51,501.3 | 54,327.2 | 56,777.6 | 59,338.5 | 62,015.0 | 64,812.1 | 67,735.4 |
| Revenue Growth, % | 0 | 3.54 | 2.61 | 6.41 | 5.49 | 4.51 | 4.51 | 4.51 | 4.51 | 4.51 |
| EBITDA | 13,417.8 | 15,711.1 | 13,245.7 | 12,830.6 | 14,745.9 | 16,145.8 | 16,874.0 | 17,635.1 | 18,430.5 | 19,261.8 |
| EBITDA, % | 29.45 | 33.31 | 27.37 | 24.91 | 27.14 | 28.44 | 28.44 | 28.44 | 28.44 | 28.44 |
| Depreciation | 3,897.0 | 3,614.4 | 5,150.6 | 4,170.3 | 3,733.0 | 4,749.7 | 4,963.9 | 5,187.8 | 5,421.8 | 5,666.4 |
| Depreciation, % | 8.55 | 7.66 | 10.64 | 8.1 | 6.87 | 8.37 | 8.37 | 8.37 | 8.37 | 8.37 |
| EBIT | 9,520.9 | 12,096.8 | 8,095.1 | 8,660.3 | 11,012.9 | 11,396.1 | 11,910.1 | 12,447.3 | 13,008.7 | 13,595.4 |
| EBIT, % | 20.9 | 25.65 | 16.73 | 16.82 | 20.27 | 20.07 | 20.07 | 20.07 | 20.07 | 20.07 |
| Total Cash | 11,743.2 | 14,811.0 | 10,129.1 | 9,218.5 | 8,904.5 | 12,763.0 | 13,338.7 | 13,940.3 | 14,569.1 | 15,226.2 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 11,381.6 | 12,496.8 | 12,838.7 | 12,360.7 | 461.5 | 11,679.6 | 12,206.3 | 12,756.9 | 13,332.3 | 13,933.6 |
| Account Receivables, % | 24.98 | 26.49 | 26.53 | 24 | 0.84945 | 20.57 | 20.57 | 20.57 | 20.57 | 20.57 |
| Inventories | 10,134.9 | 10,419.8 | 11,240.8 | 10,967.6 | 26,388.0 | 15,605.9 | 16,309.8 | 17,045.4 | 17,814.2 | 18,617.7 |
| Inventories, % | 22.25 | 22.09 | 23.23 | 21.3 | 48.57 | 27.49 | 27.49 | 27.49 | 27.49 | 27.49 |
| Accounts Payable | 7,186.9 | 7,923.0 | 8,521.9 | 8,781.3 | 26,662.4 | 13,207.4 | 13,803.1 | 14,425.7 | 15,076.3 | 15,756.3 |
| Accounts Payable, % | 15.78 | 16.8 | 17.61 | 17.05 | 49.08 | 23.26 | 23.26 | 23.26 | 23.26 | 23.26 |
| Capital Expenditure | -2,375.9 | -2,559.6 | -1,882.8 | -3,715.5 | -2,160.7 | -2,921.0 | -3,052.8 | -3,190.5 | -3,334.4 | -3,484.8 |
| Capital Expenditure, % | -5.22 | -5.43 | -3.89 | -7.21 | -3.98 | -5.14 | -5.14 | -5.14 | -5.14 | -5.14 |
| Tax Rate, % | -29.78 | -29.78 | -29.78 | -29.78 | -29.78 | -29.78 | -29.78 | -29.78 | -29.78 | -29.78 |
| EBITAT | 7,560.1 | 10,134.3 | 7,148.6 | 7,125.1 | 14,293.0 | 9,886.4 | 10,332.3 | 10,798.3 | 11,285.4 | 11,794.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -5,248.4 | 10,525.0 | 9,852.4 | 8,590.4 | 30,225.3 | -2,176.0 | 11,608.5 | 12,132.1 | 12,679.3 | 13,251.2 |
| WACC, % | 4.96 | 4.99 | 5.02 | 4.98 | 5.1 | 5.01 | 5.01 | 5.01 | 5.01 | 5.01 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 39,735.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 13,516 | |||||||||
| Terminal Value | 448,861 | |||||||||
| Present Terminal Value | 351,507 | |||||||||
| Enterprise Value | 391,242 | |||||||||
| Net Debt | 16,432 | |||||||||
| Equity Value | 374,810 | |||||||||
| Diluted Shares Outstanding, MM | 2,441 | |||||||||
| Equity Value Per Share | 153.56 |
What You Will Receive
- Comprehensive Financial Model: Sanofi’s actual data provides accurate DCF valuation.
- Complete Forecast Control: Modify revenue growth, profit margins, WACC, and other essential factors.
- Real-Time Calculations: Automatic updates allow you to see results instantly as adjustments are made.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation.
- Flexible and Reusable: Designed for adaptability, enabling repeated use for in-depth forecasts.
Key Features
- Comprehensive SNY Data: Pre-loaded with Sanofi’s historical financial performance and future outlook projections.
- Customizable Assumptions: Modify revenue growth rates, profit margins, WACC, tax implications, and capital investments.
- Interactive Valuation Model: Automatic recalculations of Net Present Value (NPV) and intrinsic value based on your adjustments.
- Scenario Analysis: Develop various forecasting scenarios to evaluate different valuation possibilities.
- User-Centric Interface: Intuitive, organized, and suitable for both seasoned professionals and newcomers.
How It Works
- Download the Template: Gain immediate access to the Excel-based SNY DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
- Instant Calculations: The model automatically recalculates Sanofi’s intrinsic value.
- Test Scenarios: Explore various assumptions to assess potential changes in valuation.
- Analyze and Decide: Utilize the findings to inform your investment or financial strategies.
Why Choose This Calculator for Sanofi (SNY)?
- Designed for Experts: A sophisticated tool utilized by financial analysts, CFOs, and industry consultants.
- Accurate Financial Data: Sanofi’s historical and projected financials are preloaded for precise analysis.
- Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
- Comprehensive Outputs: Automatically computes intrinsic value, NPV, and essential financial metrics.
- User-Friendly: Step-by-step guidance simplifies the calculation process.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling Sanofi (SNY) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models for Sanofi (SNY).
- Consultants: Deliver professional valuation insights on Sanofi (SNY) to clients quickly and accurately.
- Business Owners: Understand how large companies like Sanofi (SNY) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to Sanofi (SNY).
What the Template Contains
- Preloaded SNY Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.